Study Evaluating Renal Cell Carcinoma Risk Factors

Completed

• Conditions: Carcinoma, Renal Cell
• Interventions: Other: Epidemiological study according to clinical practice

• Registration Number: NCT00927043
• Lead Sponsor: Pfizer

Brief Summary

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

Detailed Description

invitation to volunteer

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-06-22
• Study First Submitted QC: 2009-06-23
• Study First Posted: 2009-06-24
• Primary Completion: 2011-09
• Study Completion: 2011-09
• Status Verified: 2011-11
• Last Update Submitted: 2011-11-04
• Last Update Posted: 2011-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 145

Inclusion Criteria

• Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
• =18 years, any gender.
• Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria

• Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
• Patients with other neoplasias different from RCC (current or past).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Epidemiological study according to clinical practice	-

Primary Outcome Measures

Name	Time	Method
Progression-free survival	12 months

Secondary Outcome Measures

Name	Time	Method
Overall survival.	12 months
Response rate.	12 months

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇪🇸 Pamplona, Navarra, Spain